Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
- Is Your Supply Chain Ready For The End Of Class VI?
- Demonstrating Gene Therapy Potency: A Strategic Road Map
- Why In Vivo Innovation, Regulatory Convergence Will Help Shape CGT's Next Chapter
- When Lyophilization Fails At Scale, First Scrutinize Your Formulation
- The 5 Shifts That Could Remake Lyophilization By 2040
- Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026
- Your 7 Decisions To Make Before MES Configuration
- Complete Response Letters For CGTs Share This Common Theme
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Quality Assurance In IVT RNA Vaccine Development Using Electrophoresis
Discover advanced solutions for IVT RNA synthesis, focusing on enhancing fidelity in throughput, innovative technologies, and methodologies to optimize your RNA research and development processes.
-
Expert Insights In Navigating CGT's Complex Supply Chain
Examine insights shared during Cencora's ThinkLive Cell and Gene Therapy Summit 2024 that shed light on the challenges and opportunities in navigating the complexities of the cell and gene supply chain.
-
Digital Standardization: Accelerating Gene Therapy Tech Transfer With Confidence And Compliance
Fragmented, manual data practices slow tech transfer and increase risk; centralized digital CMC systems standardize workflows, improve transparency, and accelerate onboarding while maintaining compliance.
-
Automated PUPSIT For Drug Product Applications
Automated filtration systems streamline PUPSIT, leak testing, and integrity checks to ensure sterile drug product processing. Learn how these methods improve contamination control and compliance.
-
Delivering Complex Oncology Trials At Scale
Parexel delivered two complex, global Phase III prostate cancer trials by aligning site selection, logistics, imaging workflows, and RAM regulatory expertise—achieving faster enrollment and on‑time execution.
-
Metabolic Rate Monitoring Of Undifferentiated iPS Cells And Expression Analysis Of Differentiation Markers
Continuous tracking of glucose and lactate kinetics provides clear quantitative indicators of stem cell pluripotency and early differentiation to optimize culture timing.
-
Scaling Investigational Drug Services: A Case Study in Overcoming Operational Bottlenecks
Are operational bottlenecks holding back your research site? Explore a blueprint for automating investigational product workflows and giving staff time back for patient care.
-
Enhancing Host Cell DNA Testing With Digital PCR
Residual host cell DNA testing is evolving with digital PCR. Discover how streamlined methods improve accuracy, minimize manual steps, and support efficient biopharmaceutical manufacturing processes.
-
When To Consider Material And Personnel Airlocks For Downflow Booths
Strategic use of airlocks in downflow booth design enhances pressure stability and containment. A risk-based approach ensures facility integration meets rigorous safety and compliance standards.
-
A Comprehensive Solution For Adventitious Agent Testing
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
NEWSLETTER ARCHIVE
- 10.29.26 -- Expert Insights On Choosing The Right CGT Manufacturing Model
- 10.28.26 -- Accelerating Advanced Therapies: From Development To Manufacturing
- 10.28.26 -- The Manufacturing Reality Behind Advanced Therapy Commercial Scale
- 10.28.26 -- Building More Scalable MSC Processes
- 10.28.26 -- Inside The Pursuit Of A Functional Cure For Type 1 Diabetes
- Why In Vivo Innovation, Regulatory Convergence Will Help Shape CGT's Next Chapter
- Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026
- What LSPA's Life Sciences Future Says About The Road Ahead For CGT
- Inside Scaling Next-Gen MSCs Without Scaling Risk
- Inside Kyverna's Autoimmune CAR T Platform Beyond SPS
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts
More Editorial Collections

